Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 Phase 2 RCT Results

被引：0
|
作者：
Taylor, Peter C. [1 ]
de Vlam, Kurt [2 ]
Mease, Philip J. [3 ,4 ]
Peloso, Paul M. [5 ]
Wetzel, Dieter [6 ]
Lertratanakul, Apinya [7 ]
Brun, Nikolai [8 ]
Wiens, Brian [9 ]
Brandt-Juergens, Jan
Drescher, Edit [10 ]
Dokoupilova, Eva [11 ,12 ]
Rowinska-Osuch, Anna [13 ]
Martin, Nadia Abdel-Kader [14 ]
Behrens, Frank [15 ,16 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Oxford, England
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] ACELYRIN INC, Naples, FL USA
[6] Toclinco GmbH, Freiburg, Germany
[7] ACELYRIN, Chicago, IL USA
[8] Affibody AB, Solna, Sweden
[9] ACELYRIN Inc, Half Moon Bay, CA USA
[10] Csolnoky Ferenc Hosp, Vital Med Ctr Private Clin, Veszprem, Hungary
[11] Masaryk Univ, Fac Pharm, Dept Pharmaceut Technol, Brno, Czech Republic
[12] MED PLUS Sro, Brno, Czech Republic
[13] ETG Warszawa, Warsaw, Poland
[14] Hosp Quironsalud Infanta Luisa, Seville, Spain
[15] Goethe Univ, Div Rheumatol, Univ Hosp, Frankfurt, Germany
[16] Fraunhofer Inst Translat Med & Pharmacol, Frankfurt, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1431
引用
收藏
页码：2814 / 2816
页数：3
相关论文
共 50 条
  • [31] Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
    Orbai, Ana-Maria
    Mease, Philip J.
    Helliwell, Philip S.
    FitzGerald, Oliver
    Fleishaker, Dona L.
    Mundayat, Rajiv
    Young, Pamela
    BMC RHEUMATOLOGY, 2022, 6 (01)
  • [32] Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks - Data from a Phase 4 Trial
    Gossec, Laure
    Coates, Laura
    Gladman, Dafna
    Ogdie, Alexis
    Wells, Alvin F.
    Merola, Joseph
    Gisondi, Paolo
    Pinter, Andreas
    Kishimoto, Mitsumasa
    Reddy, Jyotsna
    Amouzadeh, Hamid
    Wang, Rebecca
    Jardon, Shauna
    Brunori, Michele
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2978 - 2981
  • [33] Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
    Mease, Philip J.
    Karki, Chitra
    Palmer, Jacqueline B.
    Etzel, Carol J.
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Malley, Wendi
    Herrera, Vivian
    Tran, Melody
    Greenberg, Jeffrey D.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (11) : 1692 - 1699
  • [34] DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE AS: 12-WEEK RESULTS FROM A PHASE 2B STUDY
    van der Heijde, D.
    Gensler, L. S.
    Deodhar, A.
    Baraliakos, X.
    Poddubnyy, D.
    Farmer, M. K.
    Baeten, D.
    Kumke, T.
    Oortgiesen, M.
    Dougados, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 700 - 700
  • [35] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
    Simpson, Eric L.
    Prajapati, Vimal H.
    Leshem, Yael A.
    Chovatiya, Raj
    de Bruin-Weller, Marjolein S.
    Staender, Sonja
    Pink, Andrew E.
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique
    Ladizinski, Barry
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Liu, Meng
    Grada, Ayman
    Platt, Andrew M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
  • [36] Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
    Gladman, D. D.
    Mease, P. J.
    Cifaldi, M. A.
    Perdok, R. J.
    Sasso, E.
    Medich, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) : 163 - 168
  • [37] Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies
    Bachelez, Herve
    Griffiths, Christopher E. M.
    Papp, Kim
    Hall, Stephen
    Merola, Joseph F.
    Feldman, Steven R.
    Khraishi, Majed
    Tallman, Anna
    Tan, Huaming
    Hsu, Ming-Ann
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [38] Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
    Kristensen, Lars Erik
    Tillett, William
    Nash, Peter
    Coates, Laura C.
    Mease, Philip J.
    Ogdie, Alexis
    Gisondi, Paolo
    Ink, Barbara
    Prickett, Adam R.
    Bajracharya, Rajan
    Taieb, Vanessa
    Lyris, Nikos
    Lambert, Jeremy
    Walsh, Jessica A.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2024, 16
  • [39] Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
    Kavanaugh, Arthur
    Marzo-Ortega, Helena
    Vender, Ronald
    Birt, Julie
    Adams, David
    Benichou, Olivier
    Lin, Chen-Yen
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [40] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Marzo-Ortega, H.
    Vender, R.
    Birt, J.
    Adams, D.
    Benichou, O.
    Lin, C-Y
    Nash, P.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 39 - 40
12345